Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
[Nice-Saint-Paul de Vence 2020 recommendations for clinical practice: Management of metastatic and/or relapsing endometrial cancer].
Bull Cancer. 2020 Oct;107(10):1006-1018. doi: 10.1016/j.bulcan.2020.06.006. Epub 2020 Sep 18.
Bull Cancer. 2020.
PMID: 32958220
French.
Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study.
Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, Lesoin A, Zannetti A, N'Guyen S, Trager-Maury S, Chauvenet L, Abadie Lacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P.
Joly F, et al. Among authors: prulhiere k.
Ann Oncol. 2019 May 1;30(5):845-852. doi: 10.1093/annonc/mdz074.
Ann Oncol. 2019.
PMID: 30851097
Free article.
Item in Clipboard
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators.
Miles D, et al.
Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2.
Ann Oncol. 2021.
PMID: 34224826
Free article.
Clinical Trial.
Item in Clipboard
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Selle F, Alexandre J, Prulhière K, Kalbacher E, Ray-Coquard I, Leary A; pour le groupe GINECO.
Selle F, et al. Among authors: prulhiere k.
Bull Cancer. 2021 Dec;108(9S1):S5-S12. doi: 10.1016/S0007-4551(21)00582-8.
Bull Cancer. 2021.
PMID: 34955161
Review.
Item in Clipboard
Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022.
Selle F, Joly F, Gladieff L, Prulhière K, Leary A, Kalbacher E, Rouleau E, Ray-Coquard I.
Selle F, et al. Among authors: prulhiere k.
Bull Cancer. 2023 Jun;110(6S):6S5-6S9. doi: 10.1016/S0007-4551(23)00329-6.
Bull Cancer. 2023.
PMID: 37573039
French.
Item in Clipboard
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, Moubarak M, Rivoirard R, Polastro L, Favier L, You B, Berton D, de la Motte Rouge T, Mansi L, Abdeddaim C, Prulhiere K, Lancry Lecomte L, Provansal M, Dalban C, Ray-Coquard I.
Gauduchon T, et al. Among authors: prulhiere k.
Gynecol Oncol. 2023 Jun;173:98-105. doi: 10.1016/j.ygyno.2023.04.002. Epub 2023 Apr 25.
Gynecol Oncol. 2023.
PMID: 37105063
Item in Clipboard
Cite
Cite